FilingReader Intelligence

Symbio Pharmaceuticals raises 8.4bn yen for drug trials

July 22, 2025 at 12:06 PM UTC•By FilingReader AI

Symbio Pharmaceuticals will raise 8.35 billion yen through share options and bonds issued to EVO FUND.

The funds will finance global Phase III trials of brincidofovir for AdV infection and Phase Ib/II trials for NK/T-cell lymphoma, targeting drug approvals by 2028.

This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com

Primary Source Document

Notice regarding the issuance of the 65th to 67th series of share options (with exercise price adjustment clause) through a third-party allotment, and the execution of a repurchase agreement for the first unsecured straight bonds and share optionsJuly 22, 2025 at 08:30 AM UTC

Supplementary Source Documents

Regarding the treatment of the 58th series of share options in connection with the issuance of the 65th through 67th series of share optionsJuly 22, 2025 at 08:50 AM UTC

Symbio Pharmaceuticals Limited

TSE:4582•Tokyo Stock Exchange

RSS feed for Symbio Pharmaceuticals Limited

News Alerts

Get instant email alerts when Symbio Pharmaceuticals Limited publishes news

Free account required • Unsubscribe anytime

Browse RSS Feeds

Filing Activity Timeline

View Complete Filing History →